Impax Asset Management Group plc trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 9.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,499 shares of the company’s stock after selling 2,938 shares during the quarter. Impax Asset Management Group plc’s holdings in Eli Lilly and Company were worth $34,133,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Bridges Investment Management Inc. increased its holdings in Eli Lilly and Company by 38.5% during the 3rd quarter. Bridges Investment Management Inc. now owns 35,294 shares of the company’s stock worth $40,838,000 after purchasing an additional 9,815 shares during the period. Ironwood Investment Counsel LLC boosted its stake in shares of Eli Lilly and Company by 2.1% in the 3rd quarter. Ironwood Investment Counsel LLC now owns 3,647 shares of the company’s stock valued at $4,220,000 after buying an additional 74 shares during the period. Godfrey Financial Associates Inc. grew its position in shares of Eli Lilly and Company by 5.3% during the third quarter. Godfrey Financial Associates Inc. now owns 178 shares of the company’s stock worth $205,000 after buying an additional 9 shares in the last quarter. Vawter Financial Ltd. acquired a new position in shares of Eli Lilly and Company during the third quarter worth about $2,152,000. Finally, Edgestream Partners L.P. acquired a new position in shares of Eli Lilly and Company during the third quarter worth about $278,000. 82.53% of the stock is owned by institutional investors and hedge funds.
Trending Headlines about Eli Lilly and Company
Investors following LLY have been watching these headlines:
- Positive Sentiment: Lilly signed a cancer-research and licensing agreement with Stipple Bio worth up to $5.9 billion, using Stipple’s platform to pursue targeted therapies for solid tumors. Stipple expects to begin a Phase 1 trial in early 2027; the deal diversifies Lilly’s pipeline, though the potential value depends on development milestones. Article: Eli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio
- Neutral Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to add experimental treatments for rare blood cancers. The acquisition broadens its oncology pipeline, but clinical and regulatory milestones will determine the ultimate value and cost. Article: Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Portfolio
- Negative Sentiment: An extortion group claims it has patient and prescriber data linked to a third-party vendor serving Lilly. Lilly reportedly found no unauthorized access to its own systems, but a confirmed exposure could create privacy, regulatory and reputational concerns. Article: Eli Lilly Caught in Vendor Hack as Extortion Group Threatens to Leak Data on 1.2 Million Patients
Insider Transactions at Eli Lilly and Company
Eli Lilly and Company Stock Down 1.3%
Shares of NYSE LLY opened at $1,412.63 on Wednesday. The company has a market capitalization of $1.33 trillion, a price-to-earnings ratio of 45.85, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The business has a 50-day moving average of $1,253.71 and a two-hundred day moving average of $1,114.28. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,475.25.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same period in the prior year, the firm posted $7.02 EPS. The business’s quarterly revenue was up 38.6% compared to the same quarter last year. On average, analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is 22.46%.
Analysts Set New Price Targets
A number of research firms recently weighed in on LLY. Guggenheim upped their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. TD Cowen reiterated a “buy” rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Citigroup lifted their price target on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Bank of America reiterated a “buy” rating and set a $1,497.00 price target on shares of Eli Lilly and Company in a report on Friday, October 30th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $1,600.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,422.00.
Read Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
